How Allergan’s Mohawk tribe patent deal could blow up the IPR system
If successful, Allergan’s eye-catching gambit of seeking to cancel PTAB proceedings by assigning patents to the Saint Regis Mohawk Tribe would be a blueprint for others to follow. But will the PTAB rule that sovereign immunity applies in this case?
Patent Trial and Appeal Board (PTAB) practitioners will have no need for Restasis if Allergen’s brazen move to preserve patents for the dry eye treatment is successful. Instead, they’ll be crying about the end of the PTAB as we know...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.